Stem-cell primarily based remedy reveals promise in treating high-risk kind 1 diabetes

insulin
Credit score: Pixabay/CC0 Public Area

An investigative stem cell-based remedy referred to as PEC-Direct, designed to behave as a substitute pancreas, has the potential to offer blood sugar management in sufferers with high-risk kind 1 diabetes, suggests a medical research offered Saturday, June 11 at ENDO 2022, the Endocrine Society’s annual assembly in Atlanta, Ga.

The research discovered a number of sufferers utilizing the brand new therapy had clinically related will increase in C-peptide, a substance made within the pancreas together with insulin. C-peptide and insulin are launched from the pancreas on the identical time and in about equal quantities, so measuring C-peptide can present how a lot insulin the physique is making.

“This analysis represents the primary occasion in a number of sufferers of clinically related will increase in C-peptide, indicative of insulin manufacturing, with a stem cell-based remedy delivered in a tool,” in keeping with Manasi Sinha Jaiman, M.D., M.P.H., Chief Medical Officer of ViaCyte, Inc., in San Diego, Calif., the corporate that makes PEC-Direct.

Sufferers with kind 1 diabetes finally lose the flexibility to provide their very own insulin to manage blood sugar ranges. Sufferers should steadily test these ranges with finger sticks, inject a number of insulin pictures or carry round cumbersome gadgets. The injection of insulin additionally carries the chance of by accident decreasing blood sugar to harmful ranges.

The PEC-Direct system is designed to offer a long-term, secure supply of insulin to manage glucose ranges. The system includes a pouch containing stem-cell derived pancreatic cells which mature into insulin-producing cells as soon as implanted into the physique to manage glucose ranges. The open system membrane permits blood vessels to develop into the system to contact the cells. To forestall an immune response, sufferers take immunosuppressive medicine.

The therapy is supposed for sufferers with high-risk kind 1 diabetes, who could also be particularly susceptible to acute problems resulting from components equivalent to recurrent extreme low blood sugar, or frequent and excessive blood sugar fluctuations which are tough to manage.

The research included 10 adults with kind 1 diabetes who had obtained their analysis at the least 5 years previous to the beginning of the research and weren’t in a position to inform when their blood sugar went too low (referred to as hypoglycemia unawareness). Preliminary knowledge from one affected person confirmed clinically related ranges of stimulated C-peptide and corresponding enhancements in blood glucose management inside six months after implantation of PEC-Direct. Since then, elevated C-peptide ranges had been seen in a number of sufferers, together with decreases in HbA1C (a blood check that measures common blood sugar ranges over the previous three months) by as a lot as 1.5%, and reduces within the quantity of insulin sufferers wanted to manage by as a lot as 70%.

“The outcomes counsel stem cell-based substitute remedy has the potential to offer blood glucose management and will at some point eradicate the necessity for injecting or dosing insulin externally,” Jaiman mentioned. “The research supplies additional proof-of-concept that continued optimization of PEC-Direct has promise as a useful treatment for kind 1 diabetes.”


Mounjaro authorised for blood glucose management in kind 2 diabetes


Supplied by
The Endocrine Society

Quotation:
Stem-cell primarily based remedy reveals promise in treating high-risk kind 1 diabetes (2022, June 11)
retrieved 11 June 2022
from https://medicalxpress.com/information/2022-06-stem-cell-based-therapy-high-risk-diabetes.html

This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.